Genmab Announces Lift of Zalutumumab Partial Clinical Hold

17-Jul-2009 - Denmark

Genmab A/S announced that the US food and Drug Administration (FDA) has lifted the partial clinical hold on zalutumumab studies being conducted under an US Investigational New Drug application. Enrolment of patients can now resume in the Phase II study in patients with head and neck cancer considered incurable with standard treatment and the Phase I/II front line study of zalutumumab in combination with chemo-radiation.

"We have worked diligently to meet the FDA's request for additional zalutumumab safety information and are pleased that enrolment in the studies can be resumed so quickly," said Lisa N. Drakeman, Ph.D., Chief Executive Officer of Genmab. "We continue to believe zalutumumab could provide an important new treatment option for head and neck cancer patients with unmet medical needs."

Other news from the department research and development

Most read news

More news from our other portals

Fighting cancer: latest developments and advances